Key result
Percutaneous coronary intervention in leukemia patients is associated with a minor increase in vascular complications but no increase in cardiac complications or retroperitoneal bleeds.
Why the study?
Patients with leukemia are often denied PCI, and those who undergo the procedure are older and sicker.
Can percutaneous coronary interventions be performed safely in leukemia patients?
Observational
Can percutaneous coronary interventions be performed safely in leukemia patients?
PCI can be performed in leukemia patients without an increase in cardiac complications, though there is a minor increase in vascular complications and higher mortality driven by the underlying malignancy.
PCI may be feasible in select leukemia patients without excess cardiac risk; hypothesis-generating for malignancy-driven mortality.
Patients with leukemia are often denied percutaneous coronary intervention (PCI), and those who do undergo PCI are older and sicker. There is a minor increase in vascular complications and no increase in retroperitoneal bleeds, suggesting transfusions may be given for reasons unrelated to the PCI. Since cardiac complications are not increased in leukemia patients, the increased mortality observed in after PCI in acute leukemia may be related more to underlying malignancy.
No takes yet. Share an insight, caveat, or question.
Grines et al. (2020) conducted an observational in Leukemia requiring percutaneous coronary intervention. Percutaneous coronary intervention (PCI) was evaluated on Vascular complications, retroperitoneal bleeds, cardiac complications, and mortality. Percutaneous coronary intervention in leukemia patients is associated with a minor increase in vascular complications but no increase in cardiac complications or retroperitoneal bleeds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: